Summit Securities Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-4,600
Closed -$117K 1190
2025
Q3
$117K Buy
+4,600
New +$114K 0.02% 358
2024
Q1
Sell
-293,800
Closed -$8.46M 791
2023
Q4
$8.46M Buy
+293,800
New +$8.88M 0.76% 23
2022
Q3
Sell
-1,000
Closed -$52K 1108
2022
Q2
$52K Sell
1,000
-24,000
-96% -$1.22M 0.01% 538
2022
Q1
$1.29M Buy
25,000
+21,000
+525% +$1.09M 0.14% 117
2021
Q4
$236K Buy
4,000
+3,620
+953% +$179K 0.01% 562
2021
Q3
$1.63M Sell
380
-2,965
-89% -$131K 0.13% 182
2021
Q2
$13.1M Buy
+3,345
New +$130K 1.08% 16
2020
Q4
Sell
-182
Closed -$635K 594
2020
Q3
$635K Sell
182
-29
-14% -$1.02K 0.07% 202
2020
Q2
$654K Buy
+211
New +$7.17K 0.08% 193
2020
Q1
Sell
-2,133
Closed -$7.93M 433
2019
Q4
$7.93M Buy
+2,133
New +$76K 0.6% 38
2018
Q2
Sell
-103
Closed -$348K 247
2018
Q1
$348K Buy
+103
New +$3.54K 0.09% 106
2017
Q4
Sell
-163
Closed -$553K 237
2017
Q3
$553K Buy
+163
New +$5.24K 0.09% 99
2017
Q1
Sell
-379
Closed -$1.17M 372
2016
Q4
$1.17M Hold
379
0.25% 83
2016
Q3
$1.22M Buy
+379
New +$12.7K 0.41% 42

Other funds holding PFE

Summit Securities Group's PFE Position: Q1 2026 in Review

Summit Securities Group reduced its Pfizer (PFE) stake by 14% in Q1 2026, selling an estimated $184K and leaving 41,334 shares worth $1.16M. The position accounts for 0.14% of the portfolio, ranked #81.

Summit Securities Group first reported a position in PFE in Q2 2013 and has held it in 42 quarters since. The position peaked at $15.6M in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Summit Securities Group held 41,334 shares of Pfizer worth $1.16M as of Q1 2026.
  • Summit Securities Group sold 6,910 Pfizer shares in Q1 2026, an estimated $184K.
  • Pfizer made up 0.14% of Summit Securities Group's portfolio in Q1 2026, its #81 holding.
  • Summit Securities Group first reported a position in Pfizer in Q2 2013 and has held it in 42 quarters since.
  • Summit Securities Group's Pfizer position peaked at $15.6M in Q4 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.